Treating herpesvirus-mediated intestinal dysfunction for prevention of age-related neurodegeneration
AssigneeBattle Biotech L.L.C.
InventorRichelle Gayle Cutler
Life of this patent
Estimating the term…
Abstract
Human herpesviruses can infect barrier and immune cells of the intestines to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the brain function, and inflammation can compromise the intestinal barrier and lead to microbial translocation. Embodiments may restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Embodiments also measure HHV activity in stool by ELISA immunoassay of HHV proteins.
Claims17
A method of preventing or treating a human herpesvirus-infection in the gastrointestinal tract of a subject by oral administration of exosomes containing antiviral factors derived from colonic fibroblasts selected from the group consisting of miRNA, shRNA, mRNA, lncRNA, and a combination thereof.
A method of preventing or treating human herpesvirus infection in the gastrointestinal tract of a subject, the method comprising the oral administration of recombinant gram-negative bacteria engineered to contain a genome-integrated expression construct for expression of antiviral protein, miRNA, or both, that are exported in vesicles.
Dependencies are inferred from the claim text.